Pieris Pharmaceuticals (NASDAQ: PIRS) and Ra Pharmaceuticals (NASDAQ:RARX) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, institutional ownership, valuation, earnings, dividends, analyst recommendations and risk.
Risk & Volatility
Pieris Pharmaceuticals has a beta of 1.57, indicating that its share price is 57% more volatile than the S&P 500. Comparatively, Ra Pharmaceuticals has a beta of 2.15, indicating that its share price is 115% more volatile than the S&P 500.
50.8% of Pieris Pharmaceuticals shares are held by institutional investors. Comparatively, 69.6% of Ra Pharmaceuticals shares are held by institutional investors. 4.1% of Pieris Pharmaceuticals shares are held by company insiders. Comparatively, 14.5% of Ra Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
This table compares Pieris Pharmaceuticals and Ra Pharmaceuticals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Valuation & Earnings
This table compares Pieris Pharmaceuticals and Ra Pharmaceuticals’ gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Pieris Pharmaceuticals||$5.83 million||65.99||-$22.79 million||($0.74)||-11.61|
|Ra Pharmaceuticals||$4.93 million||28.92||-$28.86 million||($2.47)||-2.55|
Pieris Pharmaceuticals has higher revenue and earnings than Ra Pharmaceuticals. Pieris Pharmaceuticals is trading at a lower price-to-earnings ratio than Ra Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
This is a summary of current recommendations and price targets for Pieris Pharmaceuticals and Ra Pharmaceuticals, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Pieris Pharmaceuticals presently has a consensus price target of $10.00, suggesting a potential upside of 16.41%. Ra Pharmaceuticals has a consensus price target of $23.25, suggesting a potential upside of 269.05%. Given Ra Pharmaceuticals’ higher probable upside, analysts clearly believe Ra Pharmaceuticals is more favorable than Pieris Pharmaceuticals.
Ra Pharmaceuticals beats Pieris Pharmaceuticals on 6 of the 11 factors compared between the two stocks.
Pieris Pharmaceuticals Company Profile
Pieris Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company’s pipeline includes immuno-oncology multi-specifics tailored for the tumor micro-environment, an inhaled Anticalin to treat uncontrolled asthma and a half-life-optimized Anticalin to treat anemia. Its Anticalins proteins are a class of low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins typically found in blood plasma and other bodily fluids. It is focused on developing three drug candidates, which include PRS-080, PRS-060 and PRS-300 series. Its PRS-080 is an Anticalin drug candidate targeting hepcidin. The Company’s second Anticalin drug candidate, PRS-060, binds to the IL-4 receptor alpha-chain (IL-4RA), thereby inhibiting the actions of IL-4 and IL-13, two cytokines known to be mediators in the inflammatory cascade that causes asthma and other inflammatory diseases. PRS-343 is an Anticalin-based drug candidate.
Ra Pharmaceuticals Company Profile
Ra Pharmaceuticals, Inc. is a United States-based clinical-stage biopharmaceutical company. The Company focuses on the development of therapeutics for diseases of complement dysregulation and a range of orphan indications. It utilizes small molecules and peptide approaches to address pathological targets in the complement cascade. It has leveraged the Extreme Diversity peptide chemistry platform to develop a portfolio of products that selectively inhibit the complement system and other immune targets. Its main program, RA101495, is a macrocyclic peptide inhibitor of complement component 5 (C5), which is in Phase I stage of development for the treatment of paroxysmal nocturnal hemoglobinuria (PNH). RA101495 binds a site on the C5 protein to inhibit cleavage into C5a and C5b, thereby preventing red blood cell lysis by inhibiting the production and assembly of the membrane attack complex (MAC). RA101495 is being developed as an alternative to eculizumab therapy for patients with PNH.
Receive News & Ratings for Pieris Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pieris Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.